In the SURMOUNT-5 phase 3b head-to-head trial, tirzepatide produced a mean 20.2% body-weight reduction at 72 weeks, compared with 13.7% for semaglutide at maximum tolerated dose (N=751, P<0.001).1 On efficacy alone, that makes tirzepatide (sold as Zepbound for weight management and Mounjaro for Type 2 diabetes) the most effective injection currently approved by the FDA for weight loss. Semaglutide (Wegovy, Ozempic) sits second. Older once-daily liraglutide (Saxenda) is meaningfully behind both.
But "best" is rarely just about the headline percentage. Insurance coverage, monthly cost, side-effect tolerance, dose-titration speed, and access through compounding pharmacies all change the answer for individual patients. This guide walks through what the trial data actually shows, how each FDA-approved weight loss injection differs in dosing and price in 2026, and how to think about the choice with a prescriber.
Key Takeaways
- Tirzepatide (Zepbound) is the most effective FDA-approved weight loss injection based on SURMOUNT-5 head-to-head data: mean 20.2% body-weight loss at 72 weeks vs 13.7% for semaglutide.1
- Semaglutide (Wegovy) is the second most effective, with STEP-1 trial data showing a mean 14.9% body-weight loss at 68 weeks vs 2.4% on placebo (N=1,961).2
- Liraglutide (Saxenda) is older, dosed daily rather than weekly, and produces roughly 8 kg of mean weight loss over 56 weeks in the SCALE trial, substantially less than the GLP-1 / GIP options.3
- List prices are similar across brands: Wegovy lists at $1,349.02 per package; Zepbound retail averages around $1,086 per month; Ozempic lists at $997.58 per fill.456
- Manufacturer self-pay programs cut costs sharply for cash patients: Wegovy NovoCare runs $199 to $399 per month depending on dose; Zepbound LillyDirect single-dose vials run $299 to $699 per month, with the Self Pay Journey Program holding higher doses at $449 per month for refill-on-time patients.47
- Compounded semaglutide and tirzepatide remain a legitimate path for patients without insurance coverage, with disclosed-partnership review pricing as low as $150 to $349 per month depending on drug and prepay term.
What is the most effective weight loss injection?
The most effective weight loss injection currently approved by the FDA is tirzepatide, sold as Zepbound for chronic weight management. Tirzepatide is a once-weekly subcutaneous peptide that activates two incretin receptors (GLP-1 and GIP), which together reduce appetite, slow gastric emptying, and improve glucose handling. In the SURMOUNT-5 head-to-head trial published in 2025, the maximum tolerated dose of tirzepatide produced 6.5 percentage points more mean body-weight loss than the maximum tolerated dose of semaglutide over 72 weeks.1
Why tirzepatide outperforms semaglutide on average
Semaglutide acts on the GLP-1 receptor only. Tirzepatide acts on both GLP-1 and GIP receptors, which is the mechanistic differentiator. The dual-receptor agonism appears to suppress appetite more broadly and to produce greater fat-mass reduction at comparable tolerated doses. SURMOUNT-1, the original tirzepatide phase 3 weight-loss trial (N=2,539), reported mean body-weight changes of 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg at 72 weeks versus 3.1% on placebo.8 No semaglutide trial has matched the 15 mg tirzepatide arm in head-to-head conditions.
Individual response varies. Some patients lose more on semaglutide than on tirzepatide because of side-effect tolerance, adherence, dose-escalation pace, or biological response. Trial averages do not predict any one patient's outcome. The SURMOUNT-5 difference is real and statistically significant, and it does not mean tirzepatide is the right choice for every patient.
Which weight loss injections are FDA-approved?
The FDA has approved three injectable medications for chronic weight management in adults, each with specific BMI thresholds.
| Brand (active ingredient) | Class | FDA approval (weight management) | Dosing | Manufacturer |
|---|---|---|---|---|
| Zepbound (tirzepatide) | GLP-1 / GIP dual agonist | Nov 8, 2023 (and Dec 20, 2024 for OSA) | Once-weekly subcutaneous, titrated 2.5 mg → 15 mg max | Eli Lilly9 |
| Wegovy (semaglutide) | GLP-1 agonist | Jun 4, 2021 | Once-weekly subcutaneous, titrated 0.25 mg → 2.4 mg (or 7.2 mg HD) | Novo Nordisk10 |
| Saxenda (liraglutide) | GLP-1 agonist | Dec 23, 2014 | Once-daily subcutaneous, titrated 0.6 mg → 3.0 mg | Novo Nordisk11 |
Two additional injectable GLP-1 medications, Ozempic (semaglutide) and Mounjaro (tirzepatide), are FDA-approved for Type 2 diabetes rather than weight management. They are commonly prescribed off-label for weight loss because they contain the same active molecules as Wegovy and Zepbound at overlapping doses, but they are not labeled for that indication.1213 Insurance plans frequently cover Ozempic or Mounjaro only for diabetes diagnoses.
Eligibility is broadly the same across the three weight-management injections: adult BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (Type 2 diabetes, hypertension, or dyslipidemia, depending on the label).91011
How do tirzepatide and semaglutide compare in the SURMOUNT-5 trial?
SURMOUNT-5 is the first large phase 3 trial to compare tirzepatide and semaglutide head-to-head for weight management. The trial randomized 751 adults with obesity (and without Type 2 diabetes) in a 1:1 ratio to maximum tolerated tirzepatide (10 mg or 15 mg) or maximum tolerated semaglutide (1.7 mg or 2.4 mg), administered subcutaneously once weekly for 72 weeks.1
| Outcome at 72 weeks | Tirzepatide (10–15 mg) | Semaglutide (1.7–2.4 mg) |
|---|---|---|
| Mean % body-weight change | −20.2% (95% CI, −21.4 to −19.1) | −13.7% (95% CI, −14.9 to −12.6) |
| Mean waist-circumference reduction | −18.4 cm | −13.0 cm |
| Statistical significance vs comparator | P<0.001 | (reference) |
Tirzepatide produced approximately 47% more mean weight loss than semaglutide. Both arms experienced gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation), most mild to moderate and concentrated during the dose-escalation period. Treatment discontinuation rates from side effects were comparable between the two drugs.1
For a deeper look at the head-to-head data, dose ladders, and how compounded versions of each drug fit into the picture, see HMI's semaglutide vs tirzepatide comparison.
Which is better, Wegovy or Ozempic?
For weight loss, Wegovy is the better choice because it is the FDA-approved weight-management formulation of semaglutide, with insurance coverage and a dose ladder optimized for obesity (up to 2.4 mg weekly, plus a newer 7.2 mg HD option).10 Ozempic contains the same active ingredient (semaglutide) but is FDA-approved for Type 2 diabetes only, with a maximum labeled dose of 2.0 mg per week.12 Insurance plans typically reimburse Ozempic only for diabetes; using it off-label for weight loss usually means cash-pay or appealing for coverage.
The active molecule is the same. The differences that matter to patients are the indication on the label (which drives insurance coverage), the maximum dose (Wegovy reaches 2.4 mg or 7.2 mg, Ozempic stops at 2.0 mg), and the available doses on the dose ladder. For patients without diabetes who want semaglutide for weight loss, Wegovy is the on-label choice.
Which is safer, Wegovy or Mounjaro?
The two drugs share the same broad safety profile. Both can cause nausea, vomiting, diarrhea, constipation, and abdominal discomfort, especially during dose escalation. Both carry boxed warnings in the U.S. about thyroid C-cell tumors based on rodent studies; the human relevance remains uncertain, and the warnings apply equally. Both can rarely cause pancreatitis, gallbladder disease, hypoglycemia (especially with concurrent insulin or sulfonylureas), and acute kidney injury related to dehydration from severe gastrointestinal effects.1013
In SURMOUNT-5, head-to-head adverse-event rates were similar in both arms; the most common events were gastrointestinal and most were mild to moderate.1 Neither drug has demonstrated a meaningful safety advantage over the other in head-to-head data. The choice between Wegovy and Mounjaro typically comes down to the indication (Mounjaro is labeled for diabetes, not weight loss), insurance coverage, and tolerability for the individual patient.
For full side-effect detail by drug, see HMI's coverage of semaglutide side effects and tirzepatide side effects.
How long does it take to lose 20 lbs on Ozempic?
Trial averages give a ballpark. STEP-1 (semaglutide 2.4 mg, the same molecule as Ozempic) reported a mean 14.9% body-weight reduction at 68 weeks.2 For a person starting at 200 lb, that average corresponds to roughly 30 lb at 68 weeks. To hit 20 lb, that same average projection would land somewhere around 32 to 40 weeks of consistent dosing, assuming a typical titration schedule. Faster losses are common in the first few months for some patients; weight loss typically slows as the dose stabilizes.
Two important caveats. First, Ozempic is dosed up to 2.0 mg weekly, slightly below the Wegovy 2.4 mg target dose used in STEP-1, so the average expected weight loss on Ozempic is somewhat lower than the STEP-1 number.12 Second, individual variation is wide. Some patients lose more, others lose less, and a small minority do not respond. Trial averages should be read as central tendencies rather than promises.
How much do weight loss injections cost in 2026?
Brand-name weight loss injections are priced near each other at the manufacturer list level, with similar self-pay discount programs for cash patients.
| Path | Wegovy (semaglutide 2.4 mg) | Zepbound (tirzepatide) |
|---|---|---|
| Manufacturer list price | $1,349.02 / package4 | ~$1,086 / month retail7 |
| Insurance + manufacturer savings card | ~$25 / month for eligible commercial patients4 | ~$25 / month for eligible commercial patients7 |
| Manufacturer cash-pay (starter doses) | $199 / month (NovoCare, through Jun 30, 2026)4 | $299 / month (LillyDirect 2.5 mg vials)7 |
| Manufacturer cash-pay (standard doses) | $349 / month (NovoCare standard pen)4 | $449 to $699 / month (LillyDirect higher-dose vials)7 |
| Manufacturer cash-pay (top dose) | $399 / month (Wegovy 7.2 mg HD)4 | $699 / month (regular self-pay 15 mg)7 |
Two patterns to note. First, list prices are not what most patients pay. With commercial insurance and a savings card, monthly cost can drop to roughly $25 for either drug. Without insurance, the manufacturer cash-pay programs roughly match each other in the $199 to $699 range depending on dose and brand. Second, Saxenda (liraglutide) typically costs less per month at retail because it is older and dosed daily, but the lower efficacy and the daily injection cadence make it a less popular choice in 2026 than the once-weekly options.
For the full price breakdown including LillyDirect's Self Pay Journey Program (which holds the higher Zepbound doses at $449 per month for patients who refill within 45 days), see HMI's tirzepatide cost guide and the parallel semaglutide cost guide.
What about compounded weight loss injections?
Compounded semaglutide and compounded tirzepatide are versions of the active molecules made by licensed 503A or 503B compounding pharmacies, generally in cooperation with telehealth providers. They are not FDA-approved drugs in the same sense as Wegovy or Zepbound. Compounded preparations are individualized for specific patients under a prescriber's order and do not undergo the FDA's new-drug approval pathway. They are, however, a regulated practice under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
The regulatory rules shifted in 2025. After the FDA declared the semaglutide and tirzepatide shortages resolved (semaglutide on Feb 21, 2025; tirzepatide on Dec 19, 2024), enforcement-discretion windows for "essentially copies" of the commercial drugs ended in March, April, and May 2025 depending on pharmacy class.1415 Many commercial-scale compounders have since shifted toward formulations that the FDA does not classify as copies, for example semaglutide combined with B12 or other adjuvants, or tirzepatide at strengths more than 10% off the commercial product.
For patients without insurance coverage who find the manufacturer cash-pay programs out of reach, compounded semaglutide and compounded tirzepatide remain available through licensed providers. Pricing varies widely by provider, dose, and prepay term, with monthly costs ranging from roughly $150 to $600 plus typical telehealth consultation or membership fees.16 See HMI's coverage of what is compounded semaglutide and what is compounded tirzepatide for the full regulatory and clinical context.
A note on safety. Eli Lilly published an open letter in March 2026 warning that tirzepatide combined with vitamin B12 can produce a novel chemical impurity whose short- and long-term effects are unknown.17 Patients using or considering a compounded tirzepatide-plus-B12 formulation should ask their prescriber about the impurity question and the formulation's specific stability and sterility documentation.
How do I decide which weight loss injection is best for me?
There is no universally correct answer. The best injection for an individual patient depends on the variables that matter most to that patient. The framework below covers the questions a prescriber will typically work through during a consultation.
Consider efficacy first
If maximizing average weight loss is the priority and tolerability is acceptable, the head-to-head data favors tirzepatide (Zepbound).1 Patients with starting weights over a particular threshold, or with significant weight-related comorbidities, often benefit most from the larger expected reduction.
Consider insurance coverage second
Insurance plan coverage is frequently the binding constraint. Wegovy and Zepbound have similar manufacturer savings programs for commercially insured patients. Government insurance (Medicare, Medicaid) coverage of GLP-1 medications for weight management has historically been limited, though Zepbound's December 2024 FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity has expanded covered indications for tirzepatide.18
Consider tolerability and dose schedule
Some patients tolerate semaglutide better than tirzepatide, or vice versa. Both require gradual dose escalation over months to manage gastrointestinal side effects. Saxenda (liraglutide) is the daily-injection option for patients who prefer or require daily dosing for medical reasons, but its lower average efficacy makes it a second-line choice for most weight-management patients in 2026.311
Consider cost and access
For patients without insurance coverage, the manufacturer cash-pay programs (NovoCare for Wegovy, LillyDirect for Zepbound) are the cheapest path to the brand-name drug. Compounded semaglutide and tirzepatide remain a legitimate option for patients whose budget falls below those programs, with the regulatory and safety considerations covered above.
Questions to ask your prescriber
- Which medication does my insurance cover, and what is my out-of-pocket cost on each?
- Am I a candidate for the manufacturer's cash-pay program if my insurance does not cover the medication?
- What is the dose-escalation schedule, and how do I manage side effects during titration?
- Am I a candidate for the higher 7.2 mg Wegovy dose or the maximum 15 mg Zepbound dose?
- How often will we reassess weight loss progress, and when do we consider switching medications?
For patients evaluating a telehealth provider for compounded GLP-1 medications, additional questions appear in HMI's compounded-tirzepatide guide and the parallel compounded-semaglutide guide.
Frequently Asked Questions
What is the strongest injection for weight loss?
The strongest FDA-approved injection for weight loss in 2026 is tirzepatide (Zepbound). SURMOUNT-1 showed a mean 20.9% body-weight reduction at the 15 mg weekly dose over 72 weeks, and SURMOUNT-5 demonstrated tirzepatide outperforming semaglutide head-to-head (20.2% vs 13.7%) at maximum tolerated dose. Individual response varies, and tirzepatide is not necessarily the right fit for every patient.
Can you take a weight loss injection at home?
Yes. All three FDA-approved weight loss injections (Zepbound, Wegovy, Saxenda) are designed for at-home subcutaneous self-injection in the abdomen, thigh, or upper arm. Patients receive training from a prescriber or pharmacist on injection technique, typically once during the first prescription. Wegovy and Zepbound are once-weekly; Saxenda is once-daily.
How long do you stay on weight loss injections?
Weight loss injections are designed for long-term chronic weight management, not short-term use. Discontinuing the medication typically results in regaining a substantial portion of the lost weight, because the appetite-suppressing effects stop when the drug is cleared. Most prescribers plan multi-year therapy with periodic reassessment, similar to other chronic-disease medications.
Are weight loss injections safe long-term?
Long-term safety data extends to roughly five years for liraglutide, three to four years for semaglutide, and two to three years for tirzepatide based on extension trials and post-marketing surveillance. The known risks include gastrointestinal effects, gallbladder disease, pancreatitis, and a theoretical thyroid C-cell tumor risk based on rodent studies. Patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take these medications.
What is the cheapest weight loss injection?
For commercially insured patients, the cheapest path is typically either Wegovy or Zepbound at $25 per month with the manufacturer savings card.47 For cash-pay patients, Wegovy NovoCare starter doses at $199 per month are currently the lowest-cost FDA-approved option, although the offer expires June 30, 2026. Compounded semaglutide through licensed providers can run lower still, with monthly prices starting around $150 depending on prepay term and provider.
The Bottom Line
The best injection for weight loss in 2026, on the head-to-head clinical evidence, is tirzepatide (Zepbound). It produces roughly 47% more mean body-weight loss than semaglutide at maximum tolerated dose over 72 weeks, with a comparable side-effect profile. Semaglutide (Wegovy) is a strong second choice and is often the right answer for patients whose insurance covers it, who tolerate it better, or whose access situation favors it. Liraglutide (Saxenda) remains an option for patients who need daily dosing or whose prescriber selects it for a specific reason, but its lower efficacy makes it a third-line choice for most patients in 2026.
Cost varies widely by drug, dose, and access path, ranging from about $25 per month with insurance and a manufacturer savings card to roughly $1,000 to $1,350 per month at retail list price, with manufacturer cash-pay programs and compounded options filling the gap in between. The right choice for any individual patient depends on which trade-off (efficacy, tolerability, monthly cost, or availability) carries the most weight in that person's specific situation.
For prescribing decisions, work with a licensed clinician who can evaluate your medical history, weigh insurance coverage, and select the right starting dose. HMI's GLP-1 hub for tirzepatide, semaglutide hub, and Ozempic alternatives guide cover the rest of this content cluster in depth.
Written By
Rachel Nguyen, MS, RDN
Rachel is a registered dietitian with over a decade of experience in nutrition policy and the economics of health. Her current editorial focus covers GLP-1 medications, obesity medicine, and the intersection of nutrition and pharmaceutical treatment. She holds a Master of Science in Nutrition from the University of North Carolina.
Expert Reviewer
Dr. Kevin Park, PhD
Dr. Park is a nutrition education researcher focused on federal nutrition programs and dietary outcomes. His work has been published in the Journal of School Health and the Journal of the Academy of Nutrition and Dietetics. He reviewed this article's nutrition and public-health content. Clinical decisions about GLP-1 therapy should be made with a licensed prescriber.
Sources
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. 2025 Jul 3;393(1):26-36. doi:10.1056/NEJMoa2416394. PMID 40353578. ClinicalTrials.gov NCT05822830. N=751; tirzepatide −20.2% (95% CI, −21.4 to −19.1) vs semaglutide −13.7% (95% CI, −14.9 to −12.6) at 72 weeks, P<0.001. pubmed.ncbi.nlm.nih.gov/40353578. Retrieved .
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021 Mar 18;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID 33567185. N=1,961; mean −14.9% body weight at 68 weeks vs −2.4% on placebo. pubmed.ncbi.nlm.nih.gov/33567185. Retrieved .
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015 Jul 2;373(1):11-22. doi:10.1056/NEJMoa1411892. PMID 26132939. N=3,731; mean weight loss 8.4 kg vs 2.8 kg on placebo at 56 weeks. pubmed.ncbi.nlm.nih.gov/26132939. Retrieved .
- Novo Nordisk. Explaining the list price of Wegovy. NovoCare. Lists current Wegovy semaglutide injection price at $1,349.02 per package; NovoCare Pharmacy direct cash-pay $199 per month for 0.25 mg and 0.5 mg starter doses through June 30, 2026, $349 per month for standard pen doses, $399 per month for Wegovy HD 7.2 mg pen. novocare.com. Retrieved .
- Novo Nordisk. Explaining the list price of Ozempic. NovoCare. Lists current Ozempic semaglutide injection price at $997.58 across 0.25/0.5 mg, 1 mg, and 2 mg pens (with $1,027.51 shown as a prior pricing tier). novocare.com. Retrieved .
- Eli Lilly and Company. Zepbound (tirzepatide) injection, for subcutaneous use, Full Prescribing Information. FDA-approved label. DailyMed SPL setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, label revised 2/2026. Confirms 2.5 mg starting dose, 4-week titration steps, 5/10/15 mg maintenance options, subcutaneous abdomen/thigh/upper-arm administration once weekly. dailymed.nlm.nih.gov. Retrieved .
- Eli Lilly and Company. Zepbound LillyDirect self-pay vial pricing and Self Pay Journey Program. Single-dose vials $299 per month for 2.5 mg starter dose; $499 to $699 per month standard self-pay across 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg; Self Pay Journey Program holds 7.5 to 15 mg at $449 per month for patients refilling within 45 days. Pricing aggregated across LillyDirect publicly stated pricing and independent aggregators (Ro, GoodRx) as of April 2026. Cross-referenced via HMI's tirzepatide cost guide. Retrieved .
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022 Jul 21;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID 35658024. N=2,539; mean −20.9% on 15 mg, −19.5% on 10 mg, −15.0% on 5 mg vs −3.1% on placebo at 72 weeks. pubmed.ncbi.nlm.nih.gov/35658024. Retrieved .
- US Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. Press release dated November 8, 2023, announcing Zepbound (tirzepatide) approval for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity. fda.gov. Retrieved .
- US Food and Drug Administration, Drugs@FDA. Wegovy (semaglutide) NDA 215256. Original approval date: 06/04/2021 for chronic weight management. Cross-confirmed via DailyMed Wegovy label (setid ee06186f-2aa3-4990-a760-757579d8f77b, revised March 19, 2026): 0.25 mg starter through 2.4 mg or 7.2 mg HD maintenance, subcutaneous once weekly, indicated for adults with obesity, adults with overweight plus comorbidity, and pediatric patients aged 12+ with obesity. accessdata.fda.gov. Retrieved .
- US Food and Drug Administration, Drugs@FDA. Saxenda (liraglutide) NDA 206321. Original approval date: 12/23/2014 for chronic weight management in adults with obesity or overweight with comorbidity. accessdata.fda.gov. Retrieved .
- US Food and Drug Administration, Drugs@FDA. Ozempic (semaglutide) NDA 209637. Original approval date: 12/05/2017 for Type 2 diabetes mellitus. accessdata.fda.gov. Retrieved .
- US Food and Drug Administration, Drugs@FDA. Mounjaro (tirzepatide) NDA 215866. Original approval date: 05/13/2022 for Type 2 diabetes. Eli Lilly applicant. accessdata.fda.gov. Retrieved .
- US Food and Drug Administration. Resolution of Tirzepatide Injection Product Shortage and Supply Status. Declaratory order dated December 19, 2024. fda.gov/media/185577/download. Retrieved .
- US Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. Confirms semaglutide shortage resolved February 21, 2025; tirzepatide compounder dates of March 5 and March 19, 2025; 503A semaglutide enforcement-discretion end April 22, 2025; 503B semaglutide end May 22, 2025. Page also references "essentially a copy" determinations naming cyanocobalamin (B12) combinations. fda.gov. Retrieved .
- Compounded GLP-1 pricing range. Aggregated from HMI's reviews of disclosed-partnership and competitive providers, including OnlineSemaglutide, Henry Meds, and Mochi Health, as of April 2026. Each provider's pricing was verified directly against that provider's public site at the time of the relevant review.
- Eli Lilly and Company. An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12. Dated March 12, 2026. Describes a novel impurity from a chemical reaction between tirzepatide and B12 (methylcobalamin, hydroxocobalamin, or cyanocobalamin). Independently corroborated by the FDA's compounder policy page (source 15), which references cyanocobalamin in the context of "essentially a copy" determinations for compounded GLP-1s. investor.lilly.com. Retrieved via cross-reference to FDA primary source .
- US Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. Press release dated December 20, 2024, announcing Zepbound (tirzepatide) approval for moderate-to-severe obstructive sleep apnea in adults with obesity. Indication relevant to evolving Medicare and Part D coverage of tirzepatide for non-weight-management uses. fda.gov. Retrieved .